This stock popped up on my screen after the news about one of its pipeline drugs, AXS-05, got FDA fasttrack designation for treatment of agitation in patients with Alzheimer's:
http://phx.corporate-ir.net/phoenix.zht ... ID=2270682
IPO was in Nov 2015 at 8$, top jan 16 15$, now for sale at 4$, low is 3.5$.
4 Phase 3 trials with two drug candidates.
Enough cash to fund these trials, first results expected 3Q 17.
corporate presentation:
http://phx.corporate-ir.net/phoenix.zht ... sentations